North America Antibiotics Market Key Players and Opportunities by 2027

The North America antibiotics market is expected to reach US$ 18,004.25 millionby 2027 from US$ 13,527.79 million in 2019. The market is estimated to grow with a CAGR of 3.9% from 2020 to 2027.

The growth of the market is driven by factors such as prevalence of infectious diseases and increasing development of generic drugs in the North America region. However, tedious and expensive process of antibiotic development andthe impact of COVID-19 pandemic are likely to restrain the market growth to a certain extent.

Antibiotics refer to a class of medicines containing substances that are active against bacteria. These medicines either kill the bacteria or control the infection by inhibiting the bacterial reproduction, which in turn helps patient to recover. Antibiotics are specific to the type of bacteria being treated and are not able to be interchanged from one infection to another.

Generic versions are introduced in market with an aim to offer cost-efficient drugs and increase the reach of these drugs to people belonging to different economic classes. Generic versions are popular due to their availability and affordability. For instance, in June 2018, Lupin launched generic Tobramycin inhalation solution in the US market. Moreover, encouragement from government authorities is also projected to drive the production of generic antibiotics, which would eventually drive the growth of the North America antibiotics market during the forecast period.

The health systems are witnessing considerable growth in the prevalence of drug resistant bacterial infections. With various environmental factors, such as exposure to antibiotics and spontaneous mutations, bacteria are becoming highly resistant to a large number of antibiotics, and a few new antibiotics are under development in order to deal with these new bacteria strains. To combat such critical conditions, several governments and healthcare authorities are implementing constructive strategies. For instance, antibiotic resistance is a national priority, and the US government has taken ambitious steps to fight this threat. For instance, US government established a US National Strategy for Combating Antibiotic-Resistant Bacteria (National Strategy) and an accompanying US National Action Plan for Combating Antibiotic-Resistant Bacteria (National Action Plan).

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak. This has eventually shifted their focus from development of new antibiotics to vaccine development for COVID-19. Moreover, diversion of resources from antibiotics development to COVID-19 treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, pharmaceutical supplies and procurement are also badly affected by the outbreak of COVID-19 in North America.

Mexico Antibiotics Market Revenue and Forecasts to 2027 (US$Mn)

NORTH AMERICAANTIBIOTICS MARKET SEGMENTATION

By Drug Class

• Cephalosporin
• Penicillin
• Fluoroquinolones
• Macrolides
• Carbapenem
• Aminoglycosides
• Sulfonamides
• Others

By Action Mechanism

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others

By Country

• US
• Canada
• Mexico

Companies Mentioned

• Johnson & Johnson Services, Inc
• Bristol-Myers Squibb Company
• Eli Lilly and Company.
• Abbott
• Pfizer Inc

North America Antibiotics Report Scope